Genetics of Systemic Sclerosis-associated Pulmonary Arterial Hypertension: Recent Progress and Current Concepts

Overview

Journal Curr Rheumatol Rep

Publisher Current Science

Specialty Rheumatology

Date 2009 Mar 20

PMID 19296880

Citations 1

Authors

Sanjiv J Shah

Affiliations

Soon will be listed here.

Abstract

Pulmonary arterial hypertension (PAH) is a devastating complication of systemic sclerosis (SSc). Although there are screening tests for PAH, such as carbon monoxide diffusing capacity and Doppler echocardiography, these tests are far from perfect, patients are still identified late in the course of disease, and the underlying mechanisms of SSc-associated PAH are poorly understood. Understanding the genetic differences between those patients with SSc who do and do not develop PAH may improve our ability to identify and treat patients earlier in the course of disease. To date, only a few candidate gene association studies and one gene expression analysis have investigated the genetics of PAH in SSc. These studies highlight the important opportunities and challenges for exploration of genetics of complex traits. By appreciating the optimal conduct of genetic studies, along with the role of bioinformatics resources such as the International HapMap database, investigators and clinicians will be better equipped to understand the genetics of SSc-associated PAH.

Citing Articles

Pulmonary Arterial Hypertension-A Deadly Complication of Systemic Sclerosis.

Pankey E, Epps M, Nossaman B, Hyman A, Kadowitz P J Clin Rheumatol Musculoskelet Med. 2013; 1(2):11-20.

PMID: 23626904 PMC: 3636503.

References

Langleben D . Endothelin receptor antagonists in the treatment of pulmonary arterial hypertension. Clin Chest Med. 2007; 28(1):117-25, viii. DOI: 10.1016/j.ccm.2006.11.002. View

Bull T . Screening and therapy of pulmonary hypertension in systemic sclerosis. Curr Opin Rheumatol. 2007; 19(6):598-603. DOI: 10.1097/BOR.0b013e3282ec67d4. View

MacGregor A, Canavan R, Knight C, Denton C, Davar J, COGHLAN J . Pulmonary hypertension in systemic sclerosis: risk factors for progression and consequences for survival. Rheumatology (Oxford). 2001; 40(4):453-9. DOI: 10.1093/rheumatology/40.4.453. View

Coghlan J, Handler C . Connective tissue associated pulmonary arterial hypertension. Lupus. 2006; 15(3):138-42. DOI: 10.1191/0961203306lu2280rr. View

Lane K, Machado R, Pauciulo M, Thomson J, Phillips 3rd J, Loyd J . Heterozygous germline mutations in BMPR2, encoding a TGF-beta receptor, cause familial primary pulmonary hypertension. Nat Genet. 2000; 26(1):81-4. DOI: 10.1038/79226. View

Crilly A, Hamilton J, CLARK C, Jardine A, Madhok R . Analysis of transforming growth factor beta1 gene polymorphisms in patients with systemic sclerosis. Ann Rheum Dis. 2002; 61(8):678-81. PMC: 1754186. DOI: 10.1136/ard.61.8.678. View

Stewart D, Levy R, Cernacek P, Langleben D . Increased plasma endothelin-1 in pulmonary hypertension: marker or mediator of disease?. Ann Intern Med. 1991; 114(6):464-9. DOI: 10.7326/0003-4819-114-6-464. View

Julkunen H, Saijonmaa O, Gronhagen-Riska C, Teppo A, Fyhrquist F . Raised plasma concentrations of endothelin-1 in systemic lupus erythematosus. Ann Rheum Dis. 1991; 50(7):526-7. PMC: 1004476. DOI: 10.1136/ard.50.7.526-c. View

Chanock S, Manolio T, Boehnke M, Boerwinkle E, Hunter D, Thomas G . Replicating genotype-phenotype associations. Nature. 2007; 447(7145):655-60. DOI: 10.1038/447655a. View

10.

Forfia P, Fisher M, Mathai S, Housten-Harris T, Hemnes A, Borlaug B . Tricuspid annular displacement predicts survival in pulmonary hypertension. Am J Respir Crit Care Med. 2006; 174(9):1034-41. DOI: 10.1164/rccm.200604-547OC. View

11.

Thenappan T, Shah S, Rich S, Gomberg-Maitland M . A USA-based registry for pulmonary arterial hypertension: 1982-2006. Eur Respir J. 2007; 30(6):1103-10. DOI: 10.1183/09031936.00042107. View

12.

Rubin L, Badesch D . Evaluation and management of the patient with pulmonary arterial hypertension. Ann Intern Med. 2005; 143(4):282-92. DOI: 10.7326/0003-4819-143-4-200508160-00009. View

13.

Fonseca C, Renzoni E, Sestini P, Pantelidis P, Lagan A, Bunn C . Endothelin axis polymorphisms in patients with scleroderma. Arthritis Rheum. 2006; 54(9):3034-42. DOI: 10.1002/art.22036. View

14.

Mattuzzi S, Barbi S, Carletto A, Ravagnani V, Moore P, Maria Bambara L . Association of polymorphisms in the IL1B and IL2 genes with susceptibility and severity of systemic sclerosis. J Rheumatol. 2007; 34(5):997-1004. View

15.

Bull T, Coldren C, Geraci M, Voelkel N . Gene expression profiling in pulmonary hypertension. Proc Am Thorac Soc. 2007; 4(1):117-20. DOI: 10.1513/pats.200605-128JG. View

16.

Mukerjee D, St George D, Coleiro B, Knight C, Denton C, Davar J . Prevalence and outcome in systemic sclerosis associated pulmonary arterial hypertension: application of a registry approach. Ann Rheum Dis. 2003; 62(11):1088-93. PMC: 1754353. DOI: 10.1136/ard.62.11.1088. View

17.

. Proceedings of the 3rd World Symposium on Pulmonary Arterial Hypertension. Venice, Italy, June 23-25, 2003. J Am Coll Cardiol. 2004; 43(12 Suppl S):1S-90S. DOI: 10.1016/j.jacc.2004.03.003. View

18.

Newman J, Trembath R, Morse J, Grunig E, Loyd J, Adnot S . Genetic basis of pulmonary arterial hypertension: current understanding and future directions. J Am Coll Cardiol. 2004; 43(12 Suppl S):33S-39S. DOI: 10.1016/j.jacc.2004.02.028. View

19.

Tew M, Arnett F, Reveille J, Tan F . Mutations of bone morphogenetic protein receptor type II are not found in patients with pulmonary hypertension and underlying connective tissue diseases. Arthritis Rheum. 2002; 46(10):2829-30. DOI: 10.1002/art.10487. View

20.

Wang J, Prakasa K, Bomma C, Tandri H, Dalal D, James C . Comparison of novel echocardiographic parameters of right ventricular function with ejection fraction by cardiac magnetic resonance. J Am Soc Echocardiogr. 2007; 20(9):1058-64. DOI: 10.1016/j.echo.2007.01.038. View